Clinical trial
Safety and Feasibility of Human Umbilical Cord Mesenchymal Stem Cell-Derived Secretome in the Treatment of Liver Cirrhosis: a Comprehensive Evaluation of Fibrosis Reduction, Immunomodulation, and Hepatic Regeneration a Single Center, Non-randomized, Phase I Clinical Trial
NCT06629909 is registered in ClinicalTrials.gov with Baermed as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Safety and Feasibility of Human Umbilical Cord Mesenchymal Stem Cell-Derived Secretome in the Treatment of Liver Cirrhosis: a Comprehensive Evaluation of Fibrosis Reduction, Immunomodulation, and Hepatic Regeneration a Single Center, Non-randomized, Phase I Clinical Trial
- Lead sponsor
- Baermed
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- December 1, 2024
- Completion date
- October 31, 2026
- Enrollment
- 54 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.